Drug intelligence / Profile preview

Pronolis HD

Development stage: Unknown
Lead developer: Procare Health
Administration: Intraarticular

Overview

**Pronolis HD** is a branded high-density sodium hyaluronate viscosupplement developed by Procare Health for symptomatic treatment of osteoarthritis and other degenerative or traumatic disorders of synovial joints. It is a hyaluronic acid-based intra-articular injectable product intended to restore the viscoelastic properties of synovial fluid, improve joint lubrication and shock absorption, and reduce pain and functional limitation. The product is marketed in multiple concentration and dosing variants, including single-injection knee osteoarthritis presentations such as Pronolis HD Mono 2.5% and Pronolis HD One 2.2%, and is characterized as a Class III medical device rather than a conventional pharmaceutical medicine.

Brand names: Pronolis HD
Other names: Pronolis HD MonoPronolis HD One

Beyond the preview

Go deeper on Pronolis HD.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Pronolis HD.

Explore the full profile